^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

LINC02100 (Long Intergenic Non-Protein Coding RNA 2100)

i
Other names: LINC02100, Long Intergenic Non-Protein Coding RNA 2100, NONHSAG040017.2, NONHSAG040012.2, NONHSAG040007.2, NONHSAG040015.2, NONHSAG040013.2, NONHSAG040014.2, NONHSAG040016.2, HSALNG0040474, HSALNG0040478, HSALNG0040485, HSALNG0040477, HSALNG0040484, HSALNG0040481, HSALNG0040486, HSALNG0040483, HSALNG0040480, LINC02100
Associations
Trials
11ms
Identification of a C2H2 zinc finger-related lncRNA prognostic signature and its association with the immune microenvironment in clear cell renal cell carcinoma. (PubMed, Transl Androl Urol)
Common chemotherapy medications, including vinorelbine, cytarabine, epirubicin, and gemcitabine, caused increased sensitivity in the high-risk group. Additionally, the single-sample gene set enrichment analysis (ssGSEA) revealed that the immunological state of the ccRCC patients was substantially linked with the predictive parameters. The five CHZFL signature can help predict the prognosis of ccRCC patients, and assist in selecting immunotherapy and chemotherapy regimens in clinical practice.
Journal • IO biomarker
|
DBH-AS1 (DBH Antisense RNA 1) • LINC02100 (Long Intergenic Non-Protein Coding RNA 2100)
|
gemcitabine • cytarabine • epirubicin • vinorelbine tartrate
3years
Construction of a Necroptosis-Related lncRNA Signature for Predicting Prognosis and Immune Response in Kidney Renal Clear Cell Carcinoma. (PubMed, Cells)
Furthermore, this signature based on the 6 NRLs could provide a promising method to predict the prognosis and immune response of KIRC patients. To some extent, our findings helped give a reference for further research between NRLs and KIRC and find more effective therapeutic drugs for KIRC.
Journal
|
DLGAP1-AS2 (DLGAP1 Antisense RNA 2) • HOXA-AS2 (HOXA Cluster Antisense RNA 2) • LINC02100 (Long Intergenic Non-Protein Coding RNA 2100)